Roviant Sciences shares are trading lower, reversing from earlier strength after the company announced it sold its 75% stake in Telavant to Roche.
Portfolio Pulse from Benzinga Newsdesk
Roviant Sciences has sold its 75% stake in Telavant to Roche, causing its shares to trade lower after initially showing strength.
October 23, 2023 | 5:11 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Roviant Sciences' stock price is trading lower after the company sold its 75% stake in Telavant to Roche.
The sale of a significant stake in Telavant to Roche has led to a decrease in Roviant Sciences' stock price. This could be due to investors' concerns about the company's future growth prospects without Telavant.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100